Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.35, $0.08 better than the analyst estimate of $0.27. Revenue for the quarter came in at $61.8 million versus the consensus estimate of $62.1 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.